Immune checkpoint blockade for hematologic malignancies: a review

Stem Cell Investigation
Matthew J PiankoAlexander M Lesokhin

Abstract

Immune checkpoint blockade has revolutionized the treatment of cancer, with impressive responses seen in a broad variety of tumor types. Blockade of immune checkpoints and immune signaling antibodies has shown promise in multiple types of hematologic malignancies (HMs), with dramatic single agent responses for pembrolizumab and nivolumab in Hodgkin lymphoma (HL). In this review, we outline the current state of immune checkpoint blockade drug development in HMs, and discuss mechanisms of activity and resistance, and highlight potential targets in the immune tumor microenvironment (TME). Blockade of T-cell checkpoint molecules PD-1/PD-L1 and CTLA-4 are the most clinically mature of the immune checkpoint strategies. Novel and upcoming strategies for immune checkpoint blockade drug development in HMs using innovative combinations to modulate immunologic targets shows significant promise as a way to expand the number of patients with blood cancers who could benefit from immunotherapy.

Citations

Jan 25, 2018·International Journal of Molecular Sciences·Dok Hyun YoonChong Jai Kim
Feb 7, 2018·Cancer·Martin KöhlerMonika Engelhardt
Jan 10, 2018·Frontiers in Immunology·Isabel Corraliza-GorjónLeonor Kremer
Sep 14, 2018·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Carmen Mariana Aanei, Lydia Campos Catafal
Aug 21, 2018·Current Opinion in Oncology·Juan MontoroManuel Guerreiro
Mar 6, 2019·Current Oncology Reports·Jason ChuaDenise Leung
Dec 1, 2017·Pediatric Hematology and Oncology·Van HuynhMaureen M O'Brien
Nov 24, 2017·Acta Oncologica·Elisabeth Specht StovgaardEva Balslev
Oct 17, 2019·Frontiers in Oncology·Sakthi RajendranHerbert Schwarz
Nov 2, 2019·Experimental Hematology & Oncology·Kongju WuKongming Wu
Jun 6, 2018·Frontiers in Oncology·Lan V PhamRichard J Ford
Feb 14, 2019·Archives of Pharmacal Research·Sri Murugan Poongkavithai VadevooByungheon Lee
Feb 15, 2019·Journal of Clinical Medicine·Krzysztof Giannopoulos
May 31, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephen R BowenJing Zeng
Sep 14, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew J PiankoAlexander M Lesokhin
May 28, 2019·Annales de dermatologie et de vénéréologie·M CastelP Joly
Sep 3, 2020·Accounts of Chemical Research·Ling LiXiaoyuan Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Discovery Medicine
Aswin SomasundaramLiza C Villaruz
Seminars in Oncology
Blanca Homet MorenoAntoni Ribas
Current Opinion in Hematology
Stephen M Ansell
Nature Reviews. Clinical Oncology
Lisa Hutchinson
© 2022 Meta ULC. All rights reserved